Novartis Ag

Novartis Pharma Gmbh

Irm LLC

Novartis Pharma Ag

Stéphanie Monnier

Paul William Manley

David C Tully

Paul Allen Sutton

Wen-Chung Shieh

Raeann Wu

Jörg Brozio

Piotr Henryk Karpinski

Frank Stowasser

Darren Mark Legrand

Piotr “Peter” H Karpinski

Joerg Brozio

Dimitris Papoutsakis

Olivier Lohse

Jean-Louis Reber

Elias Ndzie

Silvia Heuerding

Jennifer Leslie Harris

Juergen Roettele

Dilraj Singh

Jorg Brozio

Plotr H Karpinski

Henry L Danahay

Janet C Maas

Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide are prepared by various processes.

Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

The invention relates to a new crystalline form of the acetate salt of which may be used, for example, for prevention or treatment of transplant rejection.

[object Object]

Crystalline forms of 4-methyl-N-3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide free base and salts thereof are prepared by various processes.

Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

Salts of 4-methyl N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide

Crystalline forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide free base and salts thereof are prepared by various processes.

Polymorphic forms of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide free base and salts thereof are prepared by various processes.

Compounds of formula I in salt or solvate form, wherein W, R, R, R, R, R, R, R, Rand Rand A have the meanings as indicated in the specification, are useful for treating diseases mediated by the &#x3b2;-adrenoreceptor. Pharmaceutical compositions that contain the compounds and processes for preparing the compounds are also described.

Quinolinone derivatives and their pharmaceutical compositions

Salts of 4-methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-Benzamide

This invention relates to crystal forms of aliskiren hemifumarate and various embodiments related thereto, e.g. pharmaceutical preparations, processes for the manufacture of the crystal forms, pharmaceuticals uses and the like. The crystal forms have particularly advantageous properties e.g. they are useful in the manufacture of blood-pressure lowering pharmaceutical preparations and the like.

Crystalline forms of aliskiren hemifumarate

Growing community of inventors

Raedersheim, France

Stéphanie Monnier